Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 02, 2025, titled "Zydus launches VaxiFluTM India s first trivalent influenza vaccine for flu protection".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has announced the launch of VaxiFlu™, which it describes as India's first trivalent influenza vaccine for flu protection. A trivalent vaccine covers three strains of the influenza virus in a single dose. The launch expands Zydus's presence in the domestic vaccines market and adds a new product to its growing preventive healthcare portfolio. The company has not disclosed pricing, production capacity, or revenue expectations from this product at this stage.
This is a positive product diversification move that strengthens Zydus's vaccines business, though its near-term impact on stock price may be limited until sales traction becomes visible.